<DOC>
	<DOCNO>NCT02098200</DOCNO>
	<brief_summary>The TriCinch System™ intend percutaneous treatment tricuspid regurgitation . It percutaneous catheter-based device design tricuspid valve repair order decrease effective cross-sectional area relieve symptom patient tricuspid valve regurgitation .</brief_summary>
	<brief_title>Percutaneous Treatment Tricuspid Valve Regurgitation With TriCinch System™</brief_title>
	<detailed_description>Implantation Procedure : Unlike standard open chest , arrest heart approach , 4TECH TriCinch System™ provide percutaneous solution tricuspid valve regurgitation treatment : procedure perform deep sedation , heart beating , without need respiratory assistance . The TriCinch System™ consist Delivery System enable transcatheter placement implant adjust correct Tricuspid valve regurgitation . The TriCinch Delivery System insert femoral vein access right atrium heart . At end correction process , TriCinch Delivery System venous introducer remove procedure conclude .</detailed_description>
	<mesh_term>Tricuspid Valve Insufficiency</mesh_term>
	<criteria>Functional symptomatic tricuspid regurgitation ( TR ) 2+ 4+ scale 4+ ( moderate severe ) , annular dilatation great 40mm . Signed informed consent form prior studyrelated procedure . Available able return study site postprocedural followup examination Eighteen ( 18 ) year age old . Requirement concomitant cardiac procedure ( atrial fibrillation correction surgery , closure PFO ( Patent Foramen Ovale ) ASD ( Atrial Septal Defect ) , PTCA ( percutaneous treatment coronary artery ) CAD ( coronary artery bypass surgery ) 1 3 month procedure . Presence known life threatening ( noncardiac major progressive disease ) , noncardiac disease limit subject 's life expectancy le one year . Cerebrovascular event within past 6 month . History mitral/tricuspid endocarditis within last 12 month . Organic tricuspid disease . Contraindication know allergy device 's component , aspirin , anticoagulation therapy contrast medium adequately premeditate . Severe hypertension ( SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg , measurement do sphygmomanometer stethoscope , allow patient sit least 5 minute begin BP measurement ) . Female patient pregnant ( urine HCG test result positive ) lactating . Known alcohol drug abuser . Currently participate study investigational drug device . At heart team 's judgement , patient IVC dimension adequate device implantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>tricuspid</keyword>
	<keyword>regurgitation</keyword>
	<keyword>repair</keyword>
	<keyword>outcome</keyword>
</DOC>